Objectives: Recent evidence suggests a role of androgen receptor expression as a prognostic and therapeutic biomarker in endometrial carcinoma, therefore in the present study we aimed to evaluate the frequency of androgen expression in different subtypes of endometrial carcinoma and its association with clinic-pathologic features.
Introduction
Endometrial carcinoma (EC) is one of the most common gynecological malignancies [1] . There are various histologic subtypes of EC including endometrioid, serous, clear cell, mucinous carcinoma and carcinosarcoma. These have been historically categorized into two major groups (type I and type II cancers) [2] . Endometrioid cancers are typically hormone (estrogen) driven and they are strongly linked to estrogen exposure [3] . On the other hand, recent evidence suggest that serous cancers may also be associated with hormone exposure [4, 5] . Progesterone and related compounds halts estrogen driven proliferation and they can be used in the therapy for low grade endometrioid cancers [6] . Androgens also display anti-proliferative effect in normal endometrium and therefore can theoretically play a role similar to progestins [7] . Recent studies revealed that loss of androgen receptor (AR) expression was found to be with poor survival in EC [8] . On the other hand, AR expression may serve as a potential therapeutic target in EC. Therefore, in the present study we aimed to evaluate the expression of AR in EC in our population and its association with various clinic-pathologic parameters.
Main text

Case selection
Total 103 cases of endometrial carcinoma were selected from records of pathology department archives. All patients underwent surgeries at Liaquat National hospital, Karachi from January 2012 till December 2017 over a period of 6 years. The study was approved by research and ethical review committee of Liaquat National Hospital and informed written consent was taken from all patients at the time of surgery. Hematoxylin and eosin 
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Immunohistochemistry
Androgen receptor IHC was performed using DAKO EnVision method using monoclonal mouse anti-human androgen receptor; clone AR441 according to manufacturer's protocol (dilution of 1:50). Nuclear staining for AR was both quantitatively and qualitatively evaluated. Hormone receptor IHC scoring was based on the Liverpool endometrial steroid quick score with a final score out of 12 calculated by multiplying the proportion of positive tumor nuclei (1-10% = 1, 11-20% = 2, 21-40% = 3, > 40% = 4) by the staining intensity (0 = no staining, 1 = weak, 2 = moderate, 3 = strong). Scores of 1-4 were characterized as low, scores of 5-8 were considered moderate, and scores of 9-12 were classified as high ( Fig. 1 ).
Statistical analysis
Statistical package for social sciences (SPSS 21) was used for data compilation and analysis. Mean and standard deviation were calculated for quantitative variables. Frequency and percentage were calculated for qualitative variables. Fisher exact test was applied to determine association. P value ≤ 0.05 was taken as significant. Table 2 ).
Demographic patient's profile
In the present study, we aimed to evaluate the AR expression in endometrial cancers and found that a significant proportion of endometrial cancers especially serous cancers exhibit AR expression, that may have clinical and therapeutic significance.
Variable expression of AR was seen in previous studies. Sasaki et al. reported 21% expression of AR [9] ; on the other hand, as high as 89% AR expression was detected in another study [10] . Some studies reported degree of differentiation/grade of EC to be inversely associated with AR expression [11] ; however, no such association was noted in our study. In the prior studies most of the work focused on endometrioid EC, as it seems to arise as a result of hormonal drive. In a recent study, it was noted that 70% of serous cancers and 50% of carcinosarcoma also show AR expression and high levels of AR expression was noted in half of serous carcinoma [12] . These findings correlate with results of our study as we found 42.8% serous cancers to express AR, while high AR expression was also noted in serous carcinoma. Some studies also revealed association of AR expression with good prognostic features and better disease free survival [13] ; however, we didn't found any significant association of AR expression with various pathologic parameters like tumor stage and nodal metastasis.
From a clinical standpoint, it is important to know if AR IHC expression can identify a subset of EC that can benefit from anti-androgen therapy. Recent evidence supports this speculation that androgen receptor antagonism can be a therapeutic option in EC [14, 15] . This becomes especially important in high grade endometrioid and serous cancers in which endocrine (ER/PR) therapeutic option is not available. In our study we found a high frequency of serous cancers to express AR.
Limitations
One of the major limitations of our study was lack of clinical follow up to elucidate AR expression with disease free survival and low number of cases of nonendometrioid cancer. Therefore, we suggest more large 
